Modern glucose-lowering drugs SGLT2 inhibitors and GLP-1 agonists in the prevention of cardiovascular disease and dementia in patients with diabetes and metabolic disorders
Cardiovascular diseases (CVD) and dementia are two leading causes of mortality and disability in the aging population, and their shared metabolic foundation (insulin resistance, chronic inflammation, and vascular dysfunction) opens new opportunities for pharmacological prevention. Modern glucose-lowering drugs, i.e. so...